AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease: Overview of clinical data from phase 1 and phase 2 studies
Greg Keenan(AVEO Oncology (United States)), Fatemeh Tavakkoli(AVEO Oncology (United States)), Mirjam N. Trame(AVEO Oncology (United States)), Kathy Nicholls(Melbourne Health), B. Carnley(Royal Perth Hospital), Chris Mason(Oak Ridge National Laboratory)
Cited by 0
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential
|Regenerative Medicine|2011|144